Guidance to clinicians: Cannabis-based products for medicinal use

Document first published:
Page updated:
Publication type:

Following the Government’s announcement to reschedule certain cannabis-based products for medicinal use, NHS England has provided guidance to clinicians following the re-scheduling which sets out our expectations of what this regulatory change will mean in practice for clinicians working in the NHS and in private practice in England.


A further letter has been issued which provides additional guidance to clinicians and organisations following the rescheduling of cannabis-based products for medicinal use. This clarifies the status of the clinical guidance issued, and provides further clarification in relation to synthetic cannabinoids for medicinal use.



A set of clinical frequently asked questions (FAQs) to provide further support to prescribers.